Literature DB >> 8410290

Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins.

J R Duncan1, M J Welch.   

Abstract

The mechanisms of hepatic and renal accumulation and retention of 111In-labeled proteins has been the subject of many investigations. Because the lysosome is a common intracellular destination for a variety of agents including antibodies and polypeptide hormones, we studied the in vitro and in vivo metabolism of 111In-DTPA-labeled polypeptides using a series of glycoproteins that were concentrated within the lysosome by receptor mediated endocytosis. Indium-111-DTPA-labeled glycoproteins targeted to the mannose, asialoglycoprotein and mannose 6-phosphate receptors were studied in vitro using cell lines known to express these receptors and in vivo using Sprague-Dawley rats. Once internalized, the 111In label was released slowly with 60%-90% (depending on the cell type) of the activity remaining cell associated at 24 hr. Subcellular fractionation using Percoll gradients indicated that the activity remained within the lysosome. Following internalization of the 111In-DTPA-labeled glycoproteins, the label was rapidly converted to a low molecular weight species (estimated molecular weight < or = 1000 daltons). This conversion was not seen with 111In-DTPA-alpha-galactosidase. As a lysosomal enzyme, alpha-galactosidase is relatively resistant to proteolysis within the lysosome. These results suggest that following internalization, 111In-DTPA-polypeptides are delivered to the lysosome where the polypeptide backbone can be degraded to yield 111In-DTPA-amino acid(s). These metabolites remain within the lysosome and are only slowly released from the cell. The model systems used in these studies can also be used to evaluate the intracellular metabolism of polypeptides labeled by other techniques.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410290

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  26 in total

1.  Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.

Authors:  E W Duiker; E C F Dijkers; H Lambers Heerspink; S de Jong; A G J van der Zee; P L Jager; J G W Kosterink; E G E de Vries; M N Lub-de Hooge
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery.

Authors:  H Hirabayashi; M Nishikawa; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

3.  Renal disposition of recombinant human interleukin-11 in the isolated perfused rat kidney.

Authors:  A Takagi; Y Yabe; Y Oka; K Sawai; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

4.  Characterization of LLC-PK1 kidney epithelial cells as an in vitro model for studying renal tubular reabsorption of protein drugs.

Authors:  Y Takakura; T Morita; M Fujikawa; M Hayashi; H Sezaki; M Hashida; R T Borchardt
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

5.  Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

Authors:  Edgar J Rolleman; Flavio Forrer; Bert Bernard; Magda Bijster; Marcel Vermeij; Roelf Valkema; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

6.  Pharmacokinetic and tissue distribution mechanism of mouse recombinant heat shock protein 70 in mice.

Authors:  Seiji Takemoto; Makiya Nishikawa; Yoshinobu Takakura
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

7.  Tissue retention of indium-labelled antibodies.

Authors:  A C Perkins; M V Pimm
Journal:  Eur J Nucl Med       Date:  1995-09

8.  Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo.

Authors:  Makoto Anraku; Ulrich Kragh-Hansen; Keiichi Kawai; Toru Maruyama; Yasuomi Yamasaki; Yoshinobu Takakura; Masaki Otagiri
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

9.  Efficient scavenger receptor-mediated uptake and cross-presentation of negatively charged soluble antigens by dendritic cells.

Authors:  Kohsuke Shakushiro; Yasuomi Yamasaki; Makiya Nishikawa; Yoshinobu Takakura
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

10.  Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.

Authors:  Marleen Melis; Magda Bijster; Monique de Visser; Mark W Konijnenberg; Jan de Swart; Edgar J Rolleman; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.